awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38071119-817B64B5-E58B-49E7-A001-4DE74FC0522A
Q38071119-817B64B5-E58B-49E7-A001-4DE74FC0522A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38071119-817B64B5-E58B-49E7-A001-4DE74FC0522A
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
P2860
Q38071119-817B64B5-E58B-49E7-A001-4DE74FC0522A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38071119-817B64B5-E58B-49E7-A001-4DE74FC0522A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4dfb5dc0a2366b12dcb3897c8c1e87fd1e0a8378
P2860
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.